Geode Capital Management
AXSM icon

Geode Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Geode Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$197M Buy
1,162,981
+152,732
+15% +$26.4M 0.01% 744
2025
Q4 		$185M Buy
1,010,249
+12,549
+1% +$1.75M 0.01% 752
2025
Q3 		$121M Buy
997,700
+8,247
+0.8% +$929K 0.01% 951
2025
Q2 		$103M Buy
989,453
+54,600
+6% +$5.78M 0.01% 1003
2025
Q1 		$109M Buy
934,853
+22,315
+2% +$2.54M 0.01% 930
2024
Q4 		$77.2M Buy
912,538
+4,079
+0.4% +$375K 0.01% 1158
2024
Q3 		$81.7M Buy
908,459
+23,564
+3% +$2.06M 0.01% 1126
2024
Q2 		$71.2M Buy
884,895
+39,488
+5% +$2.92M 0.01% 1128
2024
Q1 		$67.5M Buy
845,407
+23,103
+3% +$1.94M 0.01% 1163
2023
Q4 		$65.5M Buy
822,304
+43,809
+6% +$2.93M 0.01% 1156
2023
Q3 		$54.4M Buy
778,495
+68,727
+10% +$5.14M 0.01% 1178
2023
Q2 		$51M Buy
709,768
+57,332
+9% +$4.23M 0.01% 1232
2023
Q1 		$40.2M Buy
652,436
+27,847
+4% +$1.83M 0.01% 1341
2022
Q4 		$48.2M Buy
624,589
+62,000
+11% +$3.71M 0.01% 1170
2022
Q3 		$25.1M Buy
562,589
+30,837
+6% +$1.54M ﹤0.01% 1566
2022
Q2 		$20.4M Sell
531,752
-4,272
-0.8% -$135K ﹤0.01% 1760
2022
Q1 		$22.2M Buy
536,024
+28,539
+6% +$885K ﹤0.01% 1826
2021
Q4 		$19.2M Buy
507,485
+16,055
+3% +$591K ﹤0.01% 1988
2021
Q3 		$16.2M Buy
491,430
+8,180
+2% +$319K ﹤0.01% 2102
2021
Q2 		$32.6M Buy
483,250
+14,663
+3% +$880K ﹤0.01% 1655
2021
Q1 		$26.5M Buy
468,587
+41,286
+10% +$2.9M ﹤0.01% 1696
2020
Q4 		$34.8M Buy
427,301
+9,745
+2% +$729K 0.01% 1367
2020
Q3 		$29.8M Sell
417,556
-8,333
-2% -$649K 0.01% 1235
2020
Q2 		$35M Buy
425,889
+14,639
+4% +$1.13M 0.01% 1099
2020
Q1 		$24.2M Buy
411,250
+43,229
+12% +$3.52M 0.01% 1169
2019
Q4 		$38M Buy
368,021
+24,385
+7% +$985K 0.01% 1118
2019
Q3 		$6.96M Buy
343,636
+38,999
+13% +$1M ﹤0.01% 2181
2019
Q2 		$7.84M Buy
304,637
+142,183
+88% +$2.85M ﹤0.01% 2104
2019
Q1 		$2.31M Buy
162,454
+68,249
+72% +$634K ﹤0.01% 2776
2018
Q4 		$265K Hold
94,205
– – ﹤0.01% 3598
2018
Q3 		$325K Hold
94,205
– – ﹤0.01% 3594
2018
Q2 		$301K Hold
94,205
– – ﹤0.01% 3601
2018
Q1 		$230K Hold
94,205
– – ﹤0.01% 3647
2017
Q4 		$527K Hold
94,205
– – ﹤0.01% 3339
2017
Q3 		$522K Buy
94,205
+21,511
+30% +$115K ﹤0.01% 3342
2017
Q2 		$399K Buy
72,694
+14,891
+26% +$62.3K ﹤0.01% 3434
2017
Q1 		$225K Buy
57,803
+5,156
+10% +$24.6K ﹤0.01% 3616
2016
Q4 		$355K Buy
52,647
+3,517
+7% +$24.7K ﹤0.01% 3400
2016
Q3 		$387K Buy
49,130
+805
+2% +$6.09K ﹤0.01% 3351
2016
Q2 		$364K Buy
48,325
+13,862
+40% +$128K ﹤0.01% 3352
2016
Q1 		$296 Buy
+34,463
New +$316K ﹤0.01% 3487

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management's AXSM Position: Q1 2026 in Review

Geode Capital Management increased its Axsome Therapeutics (AXSM) stake by 15% in Q1 2026, buying an estimated $26.4M and bringing the position to 1,162,981 shares worth $197M. The position accounts for 0.01% of the portfolio, ranked #744.

Geode Capital Management first reported a position in AXSM in Q1 2016 and has held it in 41 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Geode Capital Management held 1,162,981 shares of Axsome Therapeutics worth $197M as of Q1 2026.
  • Geode Capital Management bought 152,732 Axsome Therapeutics shares in Q1 2026, an estimated $26.4M.
  • Axsome Therapeutics made up 0.01% of Geode Capital Management's portfolio in Q1 2026, its #744 holding.
  • Geode Capital Management first reported a position in Axsome Therapeutics in Q1 2016 and has held it in 41 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.